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year; 2002–2003, n  402). The crude incidence rates of the ﬁrst
VZV disease episode in the 3 cohorts were calculated at 1 year and
at 2 years after HCT. Multivariable Cox proportional hazard
models were used to assess the effect of ACV. In addition, we
examined the effect of long-term ACV on the incidence of ACV-
resistant HSV infection. Results: At 1 year after HCT, VZV
disease decreased from 34 per 100 person-years in cohort 1 to 4.9
in cohort 2 (P  .001) and 1.7 in cohort 3 (P  .001). The
difference persisted by 2 years (27, 7.6, 3.8 per 100 person-years,
respectively, [all comparisons P .01]). Compared to cohort 1, the
adjusted hazard ratio (HR) of developing the ﬁrst episode of VZV
disease was 0.15 (P  .001) in cohort 2 and 0.05 (P  .001) in
cohort 3 by 1 year; by 2 years the adjusted HRs were 0.30 (P 
.001) and 0.15 (P  .001), respectively. To assess the effect of
extending ACV beyond 1 year, cohorts 2 and 3 were compared and
showed a trend toward a reduced risk of VZV in cohort 3 by 2 years
(HR 0.60, P  .07). All breakthrough VZV cases responded to
treatment with ACV or Valacyclovir. During the study, 10 epi-
sodes of ACV-resistant HSV occurred in cohort 1 and 2 episodes
in cohorts 2 and 3 combined (P  .001). Conclusions: Long-term
suppressive ACV prophylaxis sharply reduces the incidence of
VZV disease during the ﬁrst year after HCT with no detectable
rebound disease after discontinuation of prophylaxis. Continuation
of ACV beyond 1 year in patients on immunosuppressive drugs
may further decrease the risk of VZV disease. Suppressive acyclovir
decreases the risk of ACV-resistant HSV infection.
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A MULTICENTER, RANDOMIZED TRIAL OF POSACONAZOLE (POS) VS
FLUCONAZOLE (FLU) OR ITRACONAZOLE (ITZ) FOR PROPHYLAXIS OF
INVASIVE FUNGAL INFECTIONS (IFIs) IN NEUTROPENIC PATIENTS
WITH ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC
SYNDROME (MDS) RECEIVING INTENSIVE CHEMOTHERAPY
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Introduction: Patients with severe and prolonged neutropenia
are at high risk for IFIs. Despite current treatment options, IFIs are
difﬁcult to treat and are associated with high mortality rates.
Antifungal prophylaxis is often used in high-risk neutropenic pa-
tients. We compared POS, an extended-spectrum triazole, to stan-
dard azoles (FLU or ITZ) for prevention of IFIs in patients with
new diagnosis or ﬁrst relapse of AML or MDS undergoing inten-
sive chemotherapy. Methods: Patients in this evaluator-blinded,
active-controlled, multicenter study were randomized to oral POS
suspension 200 mg tid or oral standard azole therapy (FLU 400 mg
qd or ITZ solution 200 mg bid) with each cycle of chemotherapy
until complete remission or for up to 12 weeks. Incidence of IFI
adjudicated by a blinded expert panel (by EORTC/MSG criteria)
was compared at end of treatment phase (primary endpoint) and
100 days postrandomization. Clinical outcome (treatment success
or failure), overall and attributable mortality, and Kaplan-Meier
analysis of time to death were also assessed. Treatment failure was
deﬁned as: proven/probable IFI; 	3 days empiric systemic anti-
fungal therapy; 	3 consecutive days or total of 10 days IV study
drug (or alternative formulation for POS); discontinuation due to
treatment-related AE; or lost to follow-up during treatment. Re-
sults: 602 patients were enrolled: 304 POS and 298 standard azole
(240 FLU, 58 ITZ). POS was superior to standard azole therapy
(FLU or ITZ) in preventing proven/probable IFIs during treat-
ment phase and 100 days postrandomization (Table). Overall mor-
tality was 49 (16%) versus 67 (22%) for patients in the POS and
standard azole arms, respectively. Kaplan-Meier analysis of time to
death (all-cause mortality) within 100 days postrandomization in-
dicated a signiﬁcant survival beneﬁt with POS (P  .035). Signif-
icantly fewer deaths were associated with IFIs in the POS arm (n
5) versus the standard azole arm (n  16; P  .012). Fewer
treatment failures occurred in the POS arm (36% vs 46%; P 
.0091). Safety and tolerability of POS and standard azoles were
comparable. Conclusions: In high-risk neutropenic patients with
AML or MDS undergoing intensive chemotherapy, POS was su-
perior to standard azole therapy (FLU or ITZ) in preventing
aspergillosis and IFIs overall. POS prophylaxis conferred a signif-
icant survival beneﬁt vs standard azole therapy. Safety and tolera-
bility were comparable between treatment arms (Table1).
Table 1.
Proven/Probable IFIs
POS FLU/ITZ
P Value
95.13%
Confidence
Interval (%)
(n  304) (n  298)
n (%) n (%)
All IFIs during treatment
phase*
7 (2) 25 (8) .0009 9.68 to 2.50
Aspergillus during
treatment phase
2 (1) 20 (7) .0001 9.05 to 3.05
All IFIs within 100 days
postrandomization
14 (5) 33 (11) .0031 10.76 to 2.17
*Treatment phase period from randomization to 7 days after last
dose of study drug.
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Background: In Taiwan, the cytomegalovirus(CMV) sero-posi-
tive rate is 	90% in the adult population. The risk of recurrent
CMV infection and CMV-associated disease may thus be higher
after allo-geneic hematopoietic stem cell transplantation (allo-
HSCT) than in Western countries. Methods: From December
1999 to December 2004, sequential monitoring of CMV antigen-
emia was performed in 186 consecutive adult patients after allo-
HSCT till day 100. CMV antigenemia was detected by pp65
antigen assay and was deﬁned as 1 positive cells/2  105 leuko-
cytes. Statistical analysis was performed to correlate the occurrence
of CMV antigenemia with clinical characteristics, transplant
events, and outcome. Results: The cumulative probability of
CMV antigenemia at day 100 was 48.7% (median onset time at
day 36): 42.5% in matched sibling donors and 81.7% in unre-
lated/HLA-mismatched donors (log rank test, P  .0001). Identi-
ﬁed risk factors by Cox regression model analysis included elder
patient age(	40 years), use of antithymocyte globulin (ATG),
steroid treatment and administration of post-engrafment gancyclo-
vir prophylaxis. CMV antigenemia was associated with increased
risk of colitis (8.9% vs 1.1%, P .015) and interstitial pneumonitis
(14.8% vs 3.2%, P  .007). Twelve patients died of CMV-related
mortality. Detection of CMV antigenemia was correlated with
signiﬁcantly inferior 1-year overall survival (38% vs 67%, P 
.0001), especially in patients transplanted at standard disease risk
stages (55% vs 91%, P  .0001), as well as 4-year overall survival
(26% vs 50%, P  .001). Post-engraftment universal ganciclovir
prophylaxis, although was effective in preventing CMV antigen-
emia, did not lead to better overall survival. Conclusions: Recur-
rent CMV infection occurred frequently after allo-HSCT and was
associated with high morbidity and mortality. Universal prophy-
laxis did not improve the overall survival in high risk patients.
Frequent monitoring of CMV status and early preemptive anti-
viral therapy was warranted in this high risk transplant group.
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